Use of thymosin alpha 1 for the treatment of cystic fibrosis
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 赛生药品股份国际有限公司
- Publication Date
- 2021-10-26
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to the use of thymosin alpha 1 (Tal) for the treatment of cystic fibrosis. More particularly, the present invention relates to the use of thymosin alpha 1 as a CFTR corrector, CFTR potentiator and anti-inflammatory agent in the treatment of cystic fibrosis. Background technique
[0002] Cystic fibrosis (CF, OMIM 219700) is a life-threatening genetic disease that primarily affects the lungs and digestive system. It is a life-limiting autosomal recessive disorder that affects 70,000 people worldwide. Patients with this disorder have steadily improved over the years, largely due to earlier diagnosis, more aggressive treatment, and care provided in specialized centers (1). Researchers now have a more complete understanding of the shortcomings of CF-based molecular biology, leading to new approaches to treatment.
[0003] CF is caused by mutations in the genetically encoded CF transmembrane conductance regulator (CFTR), whic...